ZA200208963B - Neucleotide sequences involved in increasing or decreasing mammalian ovulation rate. - Google Patents
Neucleotide sequences involved in increasing or decreasing mammalian ovulation rate. Download PDFInfo
- Publication number
- ZA200208963B ZA200208963B ZA200208963A ZA200208963A ZA200208963B ZA 200208963 B ZA200208963 B ZA 200208963B ZA 200208963 A ZA200208963 A ZA 200208963A ZA 200208963 A ZA200208963 A ZA 200208963A ZA 200208963 B ZA200208963 B ZA 200208963B
- Authority
- ZA
- South Africa
- Prior art keywords
- nucleic acid
- polypeptide
- gdf
- acid molecule
- sequence
- Prior art date
Links
- 230000016087 ovulation Effects 0.000 title claims description 56
- 230000001965 increasing effect Effects 0.000 title claims description 22
- 230000003247 decreasing effect Effects 0.000 title claims description 7
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 claims description 91
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 claims description 82
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 77
- 150000007523 nucleic acids Chemical class 0.000 claims description 73
- 108020004707 nucleic acids Proteins 0.000 claims description 68
- 102000039446 nucleic acids Human genes 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 108020004414 DNA Proteins 0.000 claims description 58
- 241000124008 Mammalia Species 0.000 claims description 56
- 241001494479 Pecora Species 0.000 claims description 54
- 239000012634 fragment Substances 0.000 claims description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 239000002773 nucleotide Substances 0.000 claims description 47
- 125000003729 nucleotide group Chemical group 0.000 claims description 46
- 239000013598 vector Substances 0.000 claims description 23
- 230000036512 infertility Effects 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 22
- 239000000523 sample Substances 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 239000003446 ligand Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 13
- 241000699670 Mus sp. Species 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 11
- 241000283690 Bos taurus Species 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 241000700159 Rattus Species 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 241000283707 Capra Species 0.000 claims description 6
- 241000282994 Cervidae Species 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 241000283086 Equidae Species 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 5
- 241000283986 Lepus Species 0.000 claims description 5
- 241000282339 Mustela Species 0.000 claims description 5
- 241000428199 Mustelinae Species 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000002823 phage display Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 5
- 230000004544 DNA amplification Effects 0.000 claims 1
- 241001649081 Dina Species 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 56
- 238000003752 polymerase chain reaction Methods 0.000 description 35
- 239000000047 product Substances 0.000 description 27
- 208000021267 infertility disease Diseases 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 18
- 239000000969 carrier Substances 0.000 description 18
- 108700028369 Alleles Proteins 0.000 description 17
- 210000001766 X chromosome Anatomy 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 208000000509 infertility Diseases 0.000 description 16
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 230000037429 base substitution Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 7
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 7
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002357 laparoscopic surgery Methods 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 244000144992 flock Species 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 101000695356 Ovis aries Bone morphogenetic protein 15 Proteins 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- 230000008217 follicular development Effects 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 2
- 108010022637 Copper-Transporting ATPases Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091007416 X-inactive specific transcript Proteins 0.000 description 2
- 108091035715 XIST (gene) Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000012173 estrus Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101150009152 Akap4 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000946377 Bos taurus Alpha-lactalbumin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000984622 Leucodon Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010033120 Ovarian agenesis Diseases 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- -1 controls Substances 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006408 female gonad development Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 102000053736 human BMP15 Human genes 0.000 description 1
- 210000004090 human X chromosome Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ500844A NZ500844A (en) | 2000-05-05 | 2000-05-05 | Nucleotide sequences (mutated GDF-9B polypeptides) involved in increasing and decreasing mammalian ovulation rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200208963B true ZA200208963B (en) | 2004-07-26 |
Family
ID=19927611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200208963A ZA200208963B (en) | 2000-05-05 | 2002-11-06 | Neucleotide sequences involved in increasing or decreasing mammalian ovulation rate. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040092007A1 (enExample) |
| EP (1) | EP1292674B1 (enExample) |
| JP (1) | JP2003532414A (enExample) |
| CN (1) | CN1436237A (enExample) |
| AR (1) | AR028411A1 (enExample) |
| AT (1) | ATE401403T1 (enExample) |
| AU (2) | AU2001260821B2 (enExample) |
| BR (1) | BR0110616A (enExample) |
| CA (1) | CA2408051A1 (enExample) |
| DE (1) | DE60134852D1 (enExample) |
| MX (1) | MXPA02010868A (enExample) |
| NZ (1) | NZ500844A (enExample) |
| RU (1) | RU2283866C2 (enExample) |
| WO (1) | WO2001085926A2 (enExample) |
| ZA (1) | ZA200208963B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502796A (en) * | 2000-06-15 | 2003-02-28 | Agres Ltd | Nucleotide and amino acid sequences of oocyte factors related to GDF-9B or GDF-9 |
| NZ519330A (en) * | 2002-05-30 | 2004-12-24 | George Henry Davis | New sequences for altering mammalian ovarian function and ovulation rate |
| AU2005310357A1 (en) * | 2004-12-02 | 2006-06-08 | Agresearch Limited | Modulation of ovulation |
| WO2007031590A1 (es) * | 2005-09-13 | 2007-03-22 | Neocodex, S.L. | Método de detección in vitro de la predisposición a desarrollar alteraciones en la función ovárica |
| ES2338960B1 (es) * | 2007-11-23 | 2011-04-19 | Carnes Oviaragon S.C.L. | Procedimiento de mejora de la productividad en ganado ovino. |
| CN105210981B (zh) * | 2015-09-15 | 2018-09-28 | 中国科学院生物物理研究所 | 建立可应用于人类疾病研究的雪貂模型的方法及其应用 |
| CN105941325A (zh) * | 2016-06-17 | 2016-09-21 | 安徽省农业科学院畜牧兽医研究所 | 小尾寒羊母羊与澳洲白公羊杂交生产澳寒杂交母羊的方法 |
| CN106614366A (zh) * | 2016-12-29 | 2017-05-10 | 李振民 | 一种无抗生猪养殖方法 |
| CN108753835A (zh) * | 2018-05-30 | 2018-11-06 | 中山大学 | 一种利用CRISPR/Cas9编辑猪BMP15基因的方法 |
| CN111440879A (zh) * | 2020-04-27 | 2020-07-24 | 内蒙古大学 | 一种利用gdf9基因提高蒙古羊繁殖力的方法 |
| CN111500744A (zh) * | 2020-04-27 | 2020-08-07 | 内蒙古大学 | 一种基于gdf9基因编码区突变的蒙古羊繁殖力提高方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
-
2000
- 2000-05-05 NZ NZ500844A patent/NZ500844A/xx not_active IP Right Cessation
-
2001
- 2001-05-04 US US10/275,503 patent/US20040092007A1/en not_active Abandoned
- 2001-05-04 EP EP01934660A patent/EP1292674B1/en not_active Expired - Lifetime
- 2001-05-04 DE DE60134852T patent/DE60134852D1/de not_active Expired - Fee Related
- 2001-05-04 AU AU2001260821A patent/AU2001260821B2/en not_active Ceased
- 2001-05-04 RU RU2002132655/13A patent/RU2283866C2/ru not_active IP Right Cessation
- 2001-05-04 AT AT01934660T patent/ATE401403T1/de not_active IP Right Cessation
- 2001-05-04 CN CN01811320A patent/CN1436237A/zh active Pending
- 2001-05-04 BR BR0110616-3A patent/BR0110616A/pt not_active IP Right Cessation
- 2001-05-04 MX MXPA02010868A patent/MXPA02010868A/es unknown
- 2001-05-04 AU AU6082101A patent/AU6082101A/xx active Pending
- 2001-05-04 WO PCT/NZ2001/000073 patent/WO2001085926A2/en not_active Ceased
- 2001-05-04 AR ARP010102128A patent/AR028411A1/es unknown
- 2001-05-04 JP JP2001582515A patent/JP2003532414A/ja active Pending
- 2001-05-04 CA CA002408051A patent/CA2408051A1/en not_active Abandoned
-
2002
- 2002-11-06 ZA ZA200208963A patent/ZA200208963B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0110616A (pt) | 2004-04-06 |
| JP2003532414A (ja) | 2003-11-05 |
| EP1292674A2 (en) | 2003-03-19 |
| AU6082101A (en) | 2001-11-20 |
| WO2001085926A3 (en) | 2002-08-08 |
| US20040092007A1 (en) | 2004-05-13 |
| AR028411A1 (es) | 2003-05-07 |
| ATE401403T1 (de) | 2008-08-15 |
| MXPA02010868A (es) | 2004-09-06 |
| RU2283866C2 (ru) | 2006-09-20 |
| DE60134852D1 (de) | 2008-08-28 |
| WO2001085926A2 (en) | 2001-11-15 |
| EP1292674B1 (en) | 2008-07-16 |
| NZ500844A (en) | 2003-06-30 |
| CA2408051A1 (en) | 2001-11-15 |
| CN1436237A (zh) | 2003-08-13 |
| AU2001260821B2 (en) | 2006-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5693757A (en) | Huntingtin DNA, protein and uses thereof | |
| US6201107B1 (en) | Cystic fibrosis gene | |
| EP1697533B1 (en) | Method for assessing the relative genetic risk for autism | |
| AU733722B2 (en) | Novel LDL-receptor | |
| US20030153035A1 (en) | Mutated bmp1b receptor as regulator of ovulation rate | |
| JP2004208694A (ja) | 嚢胞性繊維症関連遺伝子 | |
| EP1292674B1 (en) | Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate | |
| Romano et al. | Cytokeratin expression in simple epithelia: I. Identification of mRNA coding for human cytokeratin no. 18 by a cDNA clone | |
| AU2001260821A1 (en) | Nucleotide sequences involved in increasing or decreasing mammalian ovulation rate | |
| US7244577B2 (en) | Method of screening for modulator of LRP5 activity | |
| JP2001512676A (ja) | １−α−ヒドロキシラーゼの材料および方法 | |
| AU2003235525B2 (en) | New GDF-9 and GDF-9B (BMP-15) sequences for altering mammalian ovarian function and ovulation rate | |
| EP1294768A1 (en) | Mutations in spink5 responsible for netherton's syndrome and atopic diseases | |
| WO1993022435A1 (en) | Fanconi anemia gene for complementation group c | |
| US20020081592A1 (en) | Reproduction-specific genes | |
| US6555670B1 (en) | Testis-specific gene | |
| WO1998014462A1 (en) | cDNA FOR FANCONI ANEMIA COMPLEMENTATION GROUP A | |
| US7122328B2 (en) | Gene involved in mineral deposition and uses thereof | |
| EP1566386A1 (en) | A baldness related gene and the polypeptide encoded thereby, and uses thereof | |
| CA2073441C (en) | Introns and exons of the cystic fibrosis gene and mutations at various positions of the gene | |
| WO2001029266A2 (en) | Identification of arsacs mutations and methods of use therefor | |
| ZA200410311B (en) | New GDF-9 and GDF-9B (BMP-15) sequences for altering mammalian ovarian function and ovulation rate | |
| AU4807001A (en) | Ovary-specific genes and proteins | |
| WO2001047977A1 (fr) | Nouveau polypeptide, proteine p0 9, et polynucleotide codant pour ce polypeptide |